Paul-Martini-Preis

Träger des Paul-Martini-Preises

2019
Prof. Dr. med. Robert Zeiser (Freiburg/Germany)
  • Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. (Nature Medicine, 2018)
  • Oncogenic JAK2V617F causes PD-L 1 expression mediating immune-escape in myeloproliferative neoplasms. (Science Translational Medicine, 2018)
  • Neutrophils provide cellular communication between ileum and mensenteric lymph nodes at graft-versus-host disease onset. (Blood, 2018)
Weitere Informationen
2018
Prof. Dr. med. Thorsten Zenz (Zürich/Switzerland)
  • Recurrent CDKN1B (p27) mutations in hairy cell leukemia (Blood, 2015)
  • BRAF inhibition in hairy cell leukemia with low-dose vemurafenib (Blood, 2016)
  • Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations (Blood, 2017)
  • Drug-perturbation-based stratification of blood cancer (Journal of Clinical Investigation, 2018)
Weitere Informationen
2017
Prof. Dr. med. Harald Renz (Marburg/Germany)
Prof. Dr. rer. nat. Holger Garn (Marburg/Germany)
  • Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme (New Engl J Med)
Weitere Informationen
2016
Dr. med. Jan Krönke (Ulm/Germany)
  • Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells (Science 2014).
  • Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS (Nature 2015).
Weitere Informationen
2015
Prof. Dr. med. Sonja Schrepfer (Hamburg/Germany)
  • Dichloroacetate prevents restenosis in preclinical animal models of vessel injury (Nature 2014).
  • SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts (Cell Stem Cell 2014)
  • Inducing myointimal hyperplasia versus atherosclerosis in mice: An introduction of two valid models (Journal of Visualized Experiments 2014).
  • Human internal mammary artery (IMA) transplantation and stenting: a human model to study the development of in-stent restenosis (Journal of Visualized Experiments 2012).
Weitere Informationen
2014
Prof. Dr. med. Matthias Tschöp (Munich/Germany)
  • Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys and humans. (Science Translational Medicine 2013)
  • Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. (Gut 2013)
  • GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. (Diabetes 2013)
  • Targeted estrogen delivery reverses the metabolic syndrome. (Nature Medicine 2012)
Weitere Informationen
2013
Prof. Dr. med. Andreas Engert (Cologne/Germany)
  • Reduced treatment intensity in patients with early stage Hodgkin's lymphoma. (New England Journal of Medicine 2010)
  • Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. (The Lancet 2012)
  • Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. (Journal of Clinical Oncology 2010)
  • Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies – the GHSG experience. (Blood 2012)
Weitere Informationen
2012
PD Dr. med. Jan Wehkamp (Stuttgart/Germany)
  • Reduction of disulphide bonds unmasks potent antimicrobial activity of human ß-defensin 1 (Nature 2011)
Prof. Dr. med. Stephan Stilgenbauer (Ulm/Germany)
Prof. Dr. med. Michael Hallek (Köln/Germany)
  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (The Lancet 2010)
Weitere Informationen
2011
PD Dr. med. Kaan Boztug (Wien/Austria)
Prof. Dr. med. Christoph Klein (München/Germany)
  • Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome (New England Journal of Medicine 2010;363:1918-27)
Weitere Informationen

Preisträger vor 2011